Login to Your Account

Provention lands $28.4M financing to advance assets from Janssen, Finland's Vactech

By Michael Fitzhugh
Staff Writer

Monday, June 26, 2017

Provention Bio Inc., a young company advancing two phase II-ready assets from Janssen Research & Development LLC and a vaccine platform technology from Finland's Vactech Oy, has raised its first financing, $28.4 million, in a private placement of series A preferred stock that closed April 25. Provention will use proceeds of the offering to develop the assets through proof of concept.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription